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Abstract
Background: Quality and service improvement (QSI) research employs a broad range of methods to enhance the
efficiency of healthcare delivery. QSI research differs from traditional healthcare research and poses unique ethical
questions. Since QSI research aims to generate knowledge to enhance quality improvement efforts, should it be
considered research for regulatory purposes? Is review by a research ethics committee required? Should healthcare
providers be considered research participants? If participation in QSI research entails no more than minimal risk, is
consent required? The lack of consensus on answers to these questions highlights the need for ethical guidance.
Main body: Three distinct approaches to classifying QSI research in accordance with existing ethical principles and
regulations can be found in the literature. In the first approach, QSI research is viewed as distinct from other types
of healthcare research and does not require regulation. In the second approach, QSI research falls within regulatory
guidelines but is exempt from research ethics committee review. In the third approach, QSI research is deemed to
be part of the learning healthcare system and, as such, is subject to a different set of ethical principles entirely. In
this paper, we critically assess each of these views.
Conclusion: While none of these approaches is entirely satisfactory, we argue that use of the ethical principles
governing research provides the best means of addressing the numerous questions posed by QSI research.
Keywords: Quality and service improvement research, Ethics, Informed consent, Regulation, Research ethics
committees
Background
The U.S. Institute of Medicine noted that patients routinely
fail to receive high-quality, evidence-based healthcare [1].
This problem is not solely an American one, as concern
over health service delivery and patient outcome is part of a
global trend [2, 3]. Quality and service improvement (QSI)
research seeks to redress these issues by examining differ-
ent facets of the healthcare system and proposing ways to
improve delivery, outcomes, and efficiency [4]. This article
concerns QSI research, which are QSI activities that meet
the definition of research involving human participants.
This research commonly occurs in well-resourced learning
health institutions with ample healthcare staff, electronic
health record infrastructure, and experienced oversight
committees. However, features of QSI research challenge
the application of current ethics regulations. Research regu-
lations were developed with conventional randomized
controlled trials in mind where individual patients are ran-
domized to one or more experimental interventions. QSI
research differs from this paradigm in several ways: (1) QSI
research typically does not involve innovative therapy but
usual care; (2) it often intervenes on healthcare providers
rather than patients; (3) it may involve participants at mul-
tiple levels; and (4) it is usually assumed to pose no more
than minimal risk.
The Surgical Checklist Trial illustrates these differences.
Post-surgical complications are an important cause of mor-
bidity and mortality. Accordingly, in 2008, the World Health
Organization designed a surgical safety checklist to improve
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patient outcomes [5]. The Surgical Checklist Trial evaluated
the impact of this checklist on 30-day post-surgical morbid-
ity and mortality in two Norwegian hospitals [6]. The trial
employed a stepped-wedge cluster randomized design with
the units of randomization being five surgical specialties. At
the start of the trial, all five surgical specialties provided
usual care in the operating room. The order of adoption of
the 20-item checklist was randomized such that, at the end
of the trial, all five specialties were using the checklist.
Nurses in the operating room assessed and recorded phys-
ician compliance and patient outcome data were collected
from electronic health records. The research ethics commit-
tee (REC) reviewed the trial and “advised that use of rou-
tinely collected anonymized patient data is clinical service
improvement and thus no further approval or patient con-
sent is required” [6]. The trial was approved further by the
privacy ombudsman and hospital managers.
The Surgical Checklist Trial raises ethical issues common
to much QSI research: should trials that aim to improve
the quality of health services be considered research for
regulatory purposes? When is REC review required? When
the study intervention targets health providers, are they re-
search participants? And when is health provider or patient
informed consent required? Plainly, both researchers and
RECs need guidance on these (and other) issues. To date,
three approaches to accommodate QSI research within
existing regulations have been described. In this paper, we
use the Surgical Checklist Trial to illustrate these three ap-
proaches and problems associated with each. Table 1 sum-
marizes key features of each approach, implications for the
Surgical Checklist Trial, and potential problems.
Approach #1: QSI research is not research for regulatory
purposes
Existing research regulations make a sharp distinction be-
tween research and practice [7, 8]. A clear demarcation
between these two activities serves to define “the extent to
which the protections required for research [participants]
may differ from those required for patients” [9]. Research
is defined as a class of activities designed to contribute to
generalizable knowledge [10]. Practice, meanwhile, may be
defined as “a class of activities designed solely to enhance
the well-being of an individual patient” [10]. Differing
rules therefore govern their conduct. For instance,
research requires REC review, while practice does not.
Research regulations codify the norms for the ethical
conduct of research involving human participants.
The first approach, proposed by Lynn and colleagues,
classifies QSI research as distinct from other types of re-
search for regulatory purposes [11]. Since QSI research is
designed both to improve local care and to produce
generalizable knowledge, Lynn and colleagues argue that
most QSI activities do not qualify as research and, conse-
quently, do not fall within the purview of research regula-
tions or require REC review. On their view, REC review is
a “costly, cumbersome… process that is minimally rele-
vant to” and ineffective in ensuring the ethical conduct of
QSI research [11]. They suggest that the ethical oversight
of QSI research should be part of an accountability system
for professionals and the management of clinical care [11].
How would this first approach apply to the Surgical
Checklist Trial? Recall that the goal of the trial is to im-
prove service delivery to reduce postoperative morbidity
Table 1 Current approaches to accommodating QSI research within existing research regulations
Approach Key features Implications for the Surgical
Checklist Trial
Problems identified
QSI research is not research
for regulatory purposes
For regulatory purposes, QSI research
is distinct from other types of research
QSI research is designed to bring about
improvement in a local setting
The Surgical Checklist Trial is not
research, as traditionally conceived
The Surgical Checklist Trial
does not require formal research
ethics committee review
It is unclear how QSI research is
distinct from other types of research
QSI research meets the formal
definition of research
QSI is research, but is exempt
from REC review
QSI research often poses only minimal
risk and uses routinely collected data
As such, QSI research should be
exempt from review
Risks of participation are minimal
and the study only makes use of
routinely collected and anonymized
patient data
The Surgical Checklist Trial is
exempt from REC review
QSI research often involves study
interventions such as educational
programs that target human
participants
As such, QSI research is not
exempt from REC review
QSI research is part of the
learning healthcare system
and requires a new ethics
framework
Rejects the research-practice distinction
Articulates “learning” as a novel ethical
obligation
QSI research that poses only minimal
risk and does not infringe on patient
values should be integrated into clinical care
The study poses only minimal risk
and does not infringe on the rights
of participants
Surgeons and patients have an
obligation to participate in the trial
The Surgical Checklist Trial should
be integrated into the learning
healthcare system
Research and practice are distinct
There is no compelling justification
for making research participation
(“learning”) an obligation
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and mortality. As the trial seeks to improve the quality
of local surgical care, the trial should not be considered
research for regulatory purposes.
But this conclusion is problematic. While the Surgical
Checklist Trial does seek to improve care locally, it is
plainly designed to contribute to generalizable knowledge.
Indeed, the authors of the trial acknowledge as much in
saying that its findings should be “add[ed] to [the] growing
body of evidence” [6]. Further, in intervening on health
providers and collecting private health information from
patients, the trial involves human participants. It is pre-
cisely these two features—generalizable knowledge and
the involvement of human participants—that cause other
studies to be subsumed under research regulations. Thus,
the Surgical Checklist Trial should be considered research
for regulatory purposes.
Approach #2: QSI research is exempt from REC review
Research involving human participants exposes individuals
to risk—at least in part—for the benefit of others. REC re-
view is designed to ensure that research conforms to regula-
tions and, thereby, protects the liberty and welfare interests
of research participants. In a restrictive set of cases, how-
ever, research involving human participants may be exempt
from REC review. These exemptions mostly apply to re-
search that has no potential impact on participants’ inter-
ests. For instance, the U.S. Common Rule and Canada’s
Tri-Council Policy Statement classify research as exempt
from REC review only when it involves routinely collected
health information that is rigorously anonymized [12, 13].
The second approach classifies QSI research as exempt
from REC review. Proponents of this view, such as Mary
Ann Baily, argues that QSI research involves the sole use
of routinely collected patient data that have been anon-
ymized and are exempt from REC review [14]. A prime
example of this approach is the Keystone ICU Study [15,
16]. The study involved a complex intervention, includ-
ing education and a checklist, to change practitioner be-
havior and increase the use of evidence-based
procedures known to reduce the risk of infection associ-
ated with central venous catheters. The study used rou-
tinely collected data and examined group-level infection
rates. Thus, according to Bailey, “[s]uch activities should
not require [REC] review” and, indeed, the REC deemed
the Keystone study exempt from review [14, 16].
How would proponents of the second approach clas-
sify the Surgical Checklist Trial? The Surgical Checklist
Trial used routinely collected and anonymized patient
data and, according to this view, should be exempt from
REC review. Indeed, this seems to have been the view of
the responsible REC [6]. We disagree. The Surgical
Checklist Trial should have been formally reviewed by a
REC as it involved study interventions, specifically, the
use of an educational program and a checklist. These
interventions targeted surgeons and thereby implicated
their liberty and welfare interests. As research partici-
pants, health providers are entitled to the protection of
their interests afforded by REC review.
Approach #3: QSI research is part of the learning
healthcare system’s new ethical framework
The U.S. Institute of Medicine defines a learning healthcare
system as one that “is designed to generate and apply the
best evidence for the collaborative health care choices of
each patient and provider; to drive the process of discovery
as a natural outgrowth of patient care; and to ensure
innovation, quality, safety and value in health care” [17].
QSI research is integral to the learning healthcare sys-
tem as it provides the evidence used to improve health-
care delivery. But proponents of the learning healthcare
system argue that QSI research has been hindered by
“the bureaucratic burdens imposed by [REC] review pro-
cesses” [4]. Reducing such burdens requires “a clear
framework whether or not human [participant] research
requirements apply [to QSI studies] that carry no more
than minimal risk” [3].
Faden and colleagues set out a new framework to en-
sure that the learning activities in this system, including
QSI research, are conducted ethically [18]. Their frame-
work consists of seven obligations: (1) respect the rights
and dignity of patients; (2) respect clinician judgments;
(3) provide optimal clinical care to each patient; (4)
avoid imposing non-clinical risks and burdens on pa-
tients; (5) address health inequalities; (6) conduct con-
tinuous learning activities that improve the quality of
clinical care and healthcare systems; and (7) contribute
to the common purpose of improving the quality and
value of clinical care and healthcare systems.
Faden and colleagues’ framework also identifies who
bears responsibility for each obligation. The responsibil-
ity for obligations (1) through (6) falls to researchers, cli-
nicians, healthcare systems administrators, payers, and
purchasers, while the responsibility for obligation (7)
additionally falls to patients. Faden and colleagues also
state that “each of the seven moral obligations in the
framework constitutes a necessary condition…of an ad-
equate ethics,” but that “when these [obligations] come
into conflict…the goal will be to show either that one
[obligation] is of overriding importance in that context
or that at least some demands of each of the conflicting
[obligations] can be satisfied” [18]. Thus, as we under-
stand it, the obligations are prima facie, that is, required
unless outweighed by countervailing considerations.
Their framework differs from standard research regu-
lations in two ways. First, the framework stipulates that
contributing to “learning” is a moral obligation for re-
searchers, clinicians, institutions, payers, purchasers, and
patients. They explain that “all involved must appreciate
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that they are receiving care or working in an institution
committed to the shared mission of continuous learning
that feeds directly into improving patient care.” [19].
Second, they deny the research–practice distinction, and
argue that “different operational criteria for determining
which activities should be subject to oversight policies”
are needed [18]. In this proposed system, ethics over-
sight panels (distinct from RECs) will determine when
QSI research poses only minimal risk and does not in-
fringe on patient values [19]. Fiscella and colleagues sug-
gest a two-step oversight process, in which a one-page
document summarizing key ethical considerations is
reviewed by an ethics oversight panel—constituted by
investigators and previous participants of QSI research—
to either approve the project or refer it to further REC
review [20]. QSI research satisfying the operational cri-
teria will be integrated into clinical care without in-
formed consent. Institutions will notify the public that
QSI research is being conducted [19].
How would this third approach apply to the Surgical
Checklist Trial? Proponents would point out that both
healthcare providers and patients have an ethical obliga-
tion to participate in a trial that seeks to improve health
services delivery. Consultation with an oversight panel is
likely to conclude that the study poses minimal risk and
does not impact patient values significantly. Conse-
quently, the Surgical Checklist Trial ought to be inte-
grated into clinical care without seeking consent from
health providers or patients, but public notification is
required.
In our view, Faden and colleagues make the most per-
suasive argument due, in part, to their direct appeal to
ethical principles. Questions remain, however, as to the
adequacy of the learning health system framework. For
instance, do patients in fact have an obligation to partici-
pate in QSI research? What follows from this in terms of
REC review and informed consent? Might the potential
for classifying practitioner behavior as substandard nega-
tively affect their welfare interests? Finally, Faden and
colleagues provide us with no details as to how the pro-
posed framework will comply with existing regulations
and statutes.
Discussion
Our review of three different approaches to accommo-
dating QSI research in existing regulations has found
none to be wholly satisfactory. We believe that there are
two reasons for this. First, attempts to address the ethics
of QSI research by way of appeal to regulations are un-
likely to succeed. As explained above, the patient ran-
domized controlled trial designed for regulatory
approval is the paradigm for current research regula-
tions. QSI research departs from this paradigm; for one
reason, it often involves cluster randomization to usual
care or otherwise low-risk interventions that may involve
participants at multiple levels. Hence, answers are un-
likely to be found within such regulations. The first two
approaches fail for just this reason. The first approach
claims that QSI research ought not be considered re-
search for regulatory purposes because its core objective
is quality improvement. But this ignores the fact that
QSI research meets the definition of research and in-
volves human participants; in other words, the exact fea-
tures that cause activities to fall within research
regulations. The second approach seeks to exploit a
loophole found within several regulations, namely, that
research involving only routinely collected and anon-
ymized patient data is exempt. But this ignores the fact
that QSI research commonly involves study interven-
tions directed at health providers, patients, or both, who
are thus research participants.
Second, attempts to address the ethics of QSI research
by way of appeal to novel ethical principles are more
promising, but are likely to produce answers that con-
flict with existing regulations. Faden and colleagues set
out a novel ethical framework for the learning health
system comprising seven ethical principles, including a
novel obligation for health providers and patients to par-
ticipate in “learning activities.” As current regulations
are grounded in differing ethical principles (that include
no such obligation), conflict between a learning health
system approach and existing regulations is entirely pre-
dictable [21, 22]. Moreover, as recent experience has
demonstrated, effecting change to the US Common Rule
is a lengthy and complex process that can take over a
decade [23, 24].
How, then, should we proceed? We believe that direct
appeal to widely accepted research ethics principles pro-
vides the best means of addressing ethical challenges in
QSI research. Existing regulations were not written with
QSI research in mind and are unlikely to provide solu-
tions. But regulations are based on internationally ac-
cepted ethical principles, including respect for persons,
beneficence, justice, and respect for communities [7, 9,
25]. These ethical principles articulate obligations to in-
dividuals and communities in research at a level of ab-
straction that confers considerable flexibility. As they
serve as the ethical foundation for regulations, the po-
tential for conflict is minimized.
What would an ethics of QSI research grounded in re-
search ethics principles look like? Several provisional
conclusions come to mind. First, the research–practice
distinction is foundational to research ethics principles.
When a QSI activity meets the definition of research
and involves human participants, it must be reviewed by
an REC. But if there is substantial doubt as to whether
an activity meets these definitions, it is incumbent on
the investigators to ask the REC to provide a written
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determination as to whether the activity requires review
in advance of initiating the activity. We believe that this
position is both ethically required and prudent, as jour-
nals are requiring evidence of REC review for QSI re-
search [26]. However, when it is clear that a QSI activity
does not have human participants or does not meet the
definition for research, it does not need REC review.
Second, participants in QSI research must be clearly
identified, so that their interests may be protected. QSI
research commonly involves study interventions that tar-
get health providers and, in our experience, researchers
and RECs may fail to recognize this fact. Health pro-
viders who serve as research participants are a vulner-
able population in part due to their susceptibility to
coercion in the work environment and are therefore en-
titled to protection. Resnik offers several strategies for
protecting employees in research; for example: (1) re-
search proposals should describe measures to protect
the rights and welfare of employees; (2) supervisors
should not directly recruit employees and their interac-
tions should be restricted; (3) the informed consent
process should clearly indicate participation will not im-
pact employment status or benefits and an independent
party should monitor the process [27].
Third, the multi-level and complex nature of QSI re-
search has implications for the role of informed consent.
Investigators conducting QSI research may use cluster
randomized designs, in which the unit of allocation,
study interventions, and outcome measurement may dif-
fer. The Ottawa Statement for the ethical design and
conduct of cluster randomized trials provides helpful
guidance for obtaining informed consent in such designs
[28]. First, when study interventions and data collection
procedures target different individuals, informed consent
should be obtained from research participants for differ-
ent aspects of the study relevant to their participation.
Second, researchers should identify participants and seek
their informed consent before cluster randomization if
possible; if not possible, their informed consent should
be obtained as soon as possible and prior to any study
intervention or data collection procedure. Finally, a wai-
ver of consent may be appropriate when participants
cannot reasonably avoid a health system intervention
that poses only minimal risk.
Fourth, RECs should use a proportionate approach to
the review of QSI research. Studies that pose substantial
risk or involve vulnerable participants ought to receive
intensive scrutiny; QSI research that poses low risk and
does not involve vulnerable participants may undergo
expedited review. For example, the ARECCI (A pRoject
Ethics Community Consensus Initiative) Ethics Screen-
ing Tool has been implemented in Alberta Canada [29].
It is premised on the idea that all QSI activities raise eth-
ical issues, where some activities require full REC review
and others require delegated review. The ARECCI tool
separates research and non-research activities through
an electronic questionnaire that helps determine the pri-
mary purpose of the project, the types of ethical risks
and the appropriate type of ethics review [29]. Plainly,
though, a comprehensive answer to this question re-
quires further work.
Conclusion
Researchers and RECs need comprehensive guidance in
the interpretation and application of accepted ethical
principles for QSI research. Taking into consideration
the three well-intentioned, but ultimately unsuccessful,
attempts to accommodate QSI research within existing
ethical principles and regulation, the way forward is to
use established ethical principles. We draw tentative
conclusions on four issues: there is a morally relevant
distinction between research and practice; participants
of QSI research need to be clearly identified and pro-
tected; informed consent ought to be obtained, when
possible, for relevant aspects of the QSI research; and
QSI research should undergo proportionate review by
RECs.
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